Division of Adolescent Medicine, Department of Pediatrics, University of Washington & Seattle Children's Hospital.
Division of Adolescent Medicine, Department of Pediatrics, University of Washington & Seattle Children's Hospital, Seattle, Washington, USA.
Curr Opin Pediatr. 2024 Aug 1;36(4):389-399. doi: 10.1097/MOP.0000000000001357. Epub 2024 Apr 10.
This review provides an update of evidence for HIV preexposure prophylaxis (PrEP), including efficacy and safety of newly available medications. It discusses barriers to care that are unique to adolescents and young adults as well as interventions that may help increase uptake, adherence, and retention in care.
Tenofovir alafenamide-emtricitabine and cabotegravir are both newly approved medications for the prevention of HIV and are well tolerated and effective for adolescents. These medications, along with tenofovir disoproxil-emtricitabine, offer a variety of PrEP options to choose from.
Adolescents and young adults have many options when it comes to HIV prevention, but barriers persist in terms of uptake and adherence to PrEP and retention in care. Technology-based interventions, provider education, navigation support, and multiple access options are all tools to help increase PrEP use in young people.
目的综述：本综述提供了 HIV 暴露前预防 (PrEP) 的最新证据，包括新可用药物的疗效和安全性。本文讨论了青少年和年轻成人特有的护理障碍以及可能有助于提高接受度、依从性和护理保留率的干预措施。
最新发现：替诺福韦艾拉酚胺富马酸丙酚替诺福韦酯和卡替拉韦均为新批准的预防 HIV 的药物，在青少年中耐受性良好且有效。这些药物与富马酸替诺福韦二吡呋酯恩曲他滨片一起，为 PrEP 提供了多种选择。
总结：对于 HIV 预防，青少年和年轻成人有很多选择，但在接受和坚持使用 PrEP 以及保持护理方面仍然存在障碍。基于技术的干预措施、提供者教育、导航支持和多种获取途径都是帮助增加年轻人使用 PrEP 的工具。
